News

FDA took the unusual step of withdrawing approval of two cholesterol-lowering drugs late last week.

Republican presidential candidate Donald Trump recently unveiled his 7-point healthcare plan. Find out more.

At the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.

To achieve scale economies, large hospitals and healthcare systems should shift toward integrated organizations with standardized procedures and systematically reduced costs.

The CEO of the Academy of Managed Care Pharmacy identifies key challenges and opportunities that will be discussed at the annual meeting.

A new report from IMS Institute for Healthcare Informatics finds that biosimilar acceptance will grow and drive change in the healthcare system.

Covered California adopts significant new changes to its contracts with health insurers as part of an aim to take health care reform to the next level.

Comprehensive Primary Care Plus (CPC+) advanced primary care medical home model aims to strengthen primary care through a regionally-based multipayer payment reform and care delivery transformation.

A new study explores the tangible effects of the ACA and the study author weighs in on the implications for managed care.

As organizations and politicians continue to sound the alarm that drug prices are rising, another new report confirmed the trend. Total spending on medicines in the US reached $310 billion in 2015 on an estimated net price basis, up 8.5 percent from the previous year, according to a new report from the IMS Institute for Healthcare Informatics.

Experts says UnitedHealthcare’s new boutique-style health plan is designed to drive innovation in primary care.

FDA advisory committee recently voted to recommend approval of obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis (PBC). If approved, Ocaliva would be the first new treatment for PBC in nearly 20 years.

FDA recently approved venetoclax (Venclexta, AbbVie and Genentech) to treat chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least 1 prior therapy

As a result of a recent case decided by the U.S. Supreme Court, advocates of healthcare transparency may need to adjust their data collection strategies.

Following on the heels of UnitedHealthcare, Highmark weighs whether staying on the exchange marketplace will be viable.

Here are 10 solutions that come together to provide a multifaceted approach to medication adherence.

While FDA’s approval last week of infliximab-dyyb (Inflectra, Celltrion and Hospira), a biosimilar to Remicade (Janssen Biotech) for rheumatoid arthritis, Chron’s disease and other conditions is positive, FDA’s approval pace for biosimilars is too slow, according to a pharmacy benefit manager (PBM).

Medicare Advantage plans that are slow to submit risk adjustment data are at a big disadvantage.

This year’s Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2016, held April 19 to 22 in San Francisco, will feature several sessions of important to managed care professionals. Here are our top 10 recommendations.

CMS regulation will lead to major changes in Medicaid managed care programs; changes that focus on quality improvements, increased transparency and accountability, and strengthened state and federal oversight.

Some experts argue that prescription drug monitoring programs can be a game changer when it comes to curbing prescription abuse and misuse. Here are 11 states that stand out for their PDMPs (or lack thereof).

Here is an analysis of trending technologies and how they affect patient satisfaction.

A number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?

PCSK9 inhibitor benefits patients with statin intolerance

Don’t let these common misconceptions stop you from this high-impact, low-cost way to engage with patients.

Type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, according to FDA’s new Drug Safety Communication.

Telemedicine could improve diabetic patient outcomes, expand access, and provide better economic value for patients. Find out how.

Soon after FDA expanded access to the “abortion pill” or mifepristone (Mifeprex, Danco Laboratories), some states may be combating the decision.